Given that DGAT1, TYMS, and PTGS2 all play roles in mitochondrial function, the ability of SGLT2 inhibitors like empagliflozin to interact with these molecules suggests they might also exert beneficial effects on NAFLD and AF by modulating mitochondrial dysfunction. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.